World

Trump’s ‘Most Favoured Nations’ Drug Policy Raises Concerns For Indian Exporters

US President Donald Trump’s announcement of sweeping prescription drug price cuts is expected to affect global pharmaceutical markets, including India’s key generics export sector.

The move comes as the US administration pushes for international price benchmarking to bring domestic drug costs down.

Key Officials Present at Announcement

Speaking alongside Health and Human Services Secretary Robert F Kennedy Jr, Commerce Secretary Howard Lutnick, CMS Administrator Mehmet Oz, and FDA Commissioner Marty Makary, Trump declared that Americans would soon pay no more than the lowest prices charged anywhere in the world.

“You’re going to get most favoured nations pricing,” he said.

Trump stated that drugmakers had agreed to deep price reductions on major products.

“We signed historic agreements to reduce prices by 300, 400, 500, 600 and even 700 per cent,” he claimed.

Executives present at the announcement included leaders from Sanofi, Novartis, Genentech, Gilead, GSK, Merck, and Amgen, highlighting the global reach of the policy.

The President also revealed that the US would use tariffs to compel foreign governments to align drug prices with the new benchmarks.

“We would never be able to do this without the use of tariffs,” Trump said, adding that US drug prices would soon rank among the lowest in the developed world.

He further linked the initiative to expanded US-based pharmaceutical manufacturing, stating, “They’re coming in, and they’re building already.”

India, as one of the world’s largest producers of generic medicines, supplies a significant portion of affordable treatments to the US market, particularly for chronic diseases.

Indian pharmaceutical exporters are closely monitoring any US policy involving global price benchmarking, as it could affect trade and profitability, even though Indian drug prices are already among the lowest globally.

Analysts suggest that while Americans may benefit from reduced costs, global pharmaceutical companies, especially generics manufacturers in India, may face pressure on profit margins and export strategies.

Also Read: Trump Announces Ambitious Plan To Slash US Prescription Drug Prices

Geetanjali Mishra

Recent Posts

Portrait Of Former BHU Chancellor Kashi Naresh Dr Vibhuti Narayan Singh Unveiled At Malaviya Bhavan

BHU unveiled a portrait of former Chancellor and Kashi Naresh Dr Vibhuti Narayan Singh at…

2 hours ago

Sensex Jumps 898 Points; Nifty Closes Above 25,800 As Banking Stocks Lead Rally

Sensex and Nifty rallied for a second session as banking stocks gained on expectations of…

2 hours ago

PM Modi Highlights Role Of Indigenous Vaccines In Protecting Farmers’ Livestock

PM Modi highlighted indigenous vaccines' role in protecting livestock, reducing disease losses and strengthening farmers'…

3 hours ago

PM Modi Shares Sanskrit Shloka From Skanda Purana; Highlights Respect For Parents

PM Modi shared a Sanskrit verse from Skanda Purana, highlighting truth, purity, dharma and the…

3 hours ago

CM Yogi Adityanath’s Mother Savitri Devi Passes Away At 91 In Uttarakhand

Uttar Pradesh Chief Minister Yogi Adityanath’s mother, Savitri Devi, passed away at 91 at her…

5 hours ago

Gold, Silver Prices Crash Up To 6.6% As Strong Dollar Weighs On Bullion

Gold and silver prices plunged to 6.6% as a stronger dollar, rising bond yields and…

7 hours ago